Package Leaflet: Information for the User
Hydrochlorothiazide Vir 25 mg Tablets EFG
Read this package leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the Package Leaflet
This medicine contains hydrochlorothiazide as the active substance.
Hydrochlorothiazide belongs to a group of medicines known as thiazide diuretics, which increases the amount of urine, helping to reduce blood pressure.
This medicine is indicated for the treatment of the following diseases:
arterial hypertension in adults
Do not take Hydrochlorothiazide Vir:
Warnings and precautions
Talk to your doctor or pharmacist before taking this medicine.
Be especially careful in the following situations:
Taking Hydrochlorothiazide Vir with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
The following medicines may interact with hydrochlorothiazide when used at the same time:
Taking Hydrochlorothiazide Vir with food, drinks, and alcohol
In combination with alcohol consumption, this medicine may cause dizziness, drowsiness, or headache.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Pregnancy
Usually, your doctor will advise you to stop taking Hydrochlorothiazide Vir before becoming pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of Hydrochlorothiazide Vir.
Hydrochlorothiazide Vir is not recommended during pregnancy. This is because hydrochlorothiazide crosses the placenta and its use after the first trimester of pregnancy may cause potentially harmful effects on the fetus and newborn.
Breastfeeding
Tell your doctor if you are breastfeeding or plan to breastfeed.
Hydrochlorothiazide is excreted in breast milk, so its use is not recommended in breastfeeding mothers.
Fertility
No data are available in humans. Animal studies do not show effects on fertility.
Driving and using machines
It is unlikely that hydrochlorothiazide will affect your ability to drive or use machines.
Hydrochlorothiazide Vir contains lactose
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine.
Use in athletes
Athletes are informed that this medicine contains a component that may result in a positive doping test
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.
The usual doses are:
Method of administration
The tablets should be taken orally, with or without food.
The tablet can be divided into two equal halves.
If you take more Hydrochlorothiazide Vir than you should
If you have taken more Hydrochlorothiazide Vir than you should, consult your doctor, pharmacist, or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medicine and the amount used.
The following signs and symptoms may occur in the event of overdose: dizziness, nausea, drowsiness, decreased blood circulation (hypovolemia), low blood pressure (hypotension), and electrolyte disorders associated with cardiac arrhythmias and muscle spasms.
If you forget to take Hydrochlorothiazide Vir
Do not take a double dose to make up for forgotten doses.
If you stop taking Hydrochlorothiazide Vir
Treatment of hypertension is a long-term treatment, and stopping this treatment should be consulted with your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Very common side effects (may affect more than 1 in 10 people):
Common side effects (may affect up to 1 in 10 people):
Rare side effects (may affect up to 1 in 1,000 people):
Very rare side effects (may affect up to 1 in 10,000 people):
Frequency "not known": Skin and lip cancer (non-melanoma skin cancer).
Post-marketing experience
The following adverse reactions have been identified during post-marketing experience. Since these reactions have been reported voluntarily from a population of uncertain size, it is not possible to estimate their frequency.
Unknown frequency: weakness, frequent infections, and bruising (aplastic anemia), acute kidney failure, kidney disorder, skin rash, blisters on the lips, eyes, or mouth; skin peeling, fever (possible signs of erythema multiforme), pyrexia, muscle spasms, asthenia, decreased vision or eye pain due to increased pressure [possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma].
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if it is possible side effects not listed in this package leaflet. You can also report side effects directly through the Spanish Medicines Agency's online platform: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Store in the original packaging to protect from light
Do not use this medicine after the expiry date which is stated on the packaging after EXP. The expiry date is the last day of the month shown.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Hydrochlorothiazide Vir
Appearance of the product and packaging
Hydrochlorothiazide Vir 25 mg tablets are white, round, flat tablets with a score line.
Hydrochlorothiazide Vir is packaged in blisters and is available in packs containing 20 tablets.
Marketing authorization holder and manufacturer
Marketing authorization holder
Industria Química y Farmacéutica VIR, S.A.
C/ Laguna 66-70, Polígono Industrial URTINSA II
28923 Alcorcón (Madrid)
Spain
Manufacturer
Pharmaceuticals Works Polpharma S.A
19 Pelplinska Street, Starogard, Gdanski, Poland
or
Industria Química y Farmacéutica VIR, S.A.
C/ Laguna 66-70, Polígono Industrial Urtinsa II
28923 Alcorcón (Madrid)
Spain
This product is authorized in other European Economic Area (EEA) countries with the following names:
Date of last revision of this package leaflet:June 2024
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
The average price of HYDROCHLOROTHIAZIDE VIR 25 mg TABLETS in October, 2025 is around 2.34 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.